The scale of the problem

The United States has the highest obesity rate of any large developed nation. According to the CDC's National Health and Nutrition Examination Survey, 41.9% of American adults were obese as of 2020. Another 30.7% were overweight. Combined, nearly three out of four adults in the country are above a healthy weight.

These numbers have been climbing for decades. In 1960, 13% of adults were obese. By 1990, it was 23%. By 2010, it hit 36%. The curve has not flattened.

By the numbers: 41.9% of US adults are obese (BMI 30+), 9.2% are severely obese (BMI 40+), and 19.7% of children ages 2 to 19 are obese. The US spends hundreds of billions annually on obesity-related medical costs.

How the US compares globally

Among OECD nations, the United States leads in adult obesity by a wide margin. Japan's rate is 4.5%. South Korea's is 5.9%. France and Italy sit around 17%. Even the United Kingdom, which frequently makes headlines about its own weight crisis, comes in at 28%, a full 14 points behind the US.

The disparity is hard to explain with genetics alone. Americans who immigrate from low-obesity countries see their BMI rise within years of arrival. The environment, not biology, is doing most of the heavy lifting.

It is not evenly distributed

Obesity rates vary sharply by geography, income, and race. Mississippi leads with 40.8% of adults obese. Colorado sits lowest at 25.1%. Rural counties consistently outpace urban ones.

Income plays a major role. Adults living below the federal poverty line have obesity rates roughly 10 percentage points higher than those in the highest income bracket. Food deserts and limited access to healthcare compound the problem.

Racial disparities are stark. Non-Hispanic Black adults have the highest obesity rate at 49.9%, followed by Hispanic adults at 45.6%, non-Hispanic white adults at 41.4%, and non-Hispanic Asian adults at 16.1%.

What obesity actually does to the body

Obesity is a metabolic disease, not a cosmetic one. It drives a long list of downstream conditions:

  • Type 2 diabetes: 89% of people with type 2 diabetes are overweight or obese
  • Heart disease: Obesity increases the risk of coronary heart disease by 50 to 100%
  • Cancer: At least 13 types of cancer are linked to excess body weight, including breast, colon, kidney, and pancreatic
  • Sleep apnea: Present in roughly 45% of people with obesity
  • Joint disease: Every pound of excess weight adds roughly four pounds of pressure on the knees
  • Mental health: Obesity is associated with a 55% increased risk of depression

Life expectancy in the United States has stalled relative to other wealthy nations, and obesity is a primary driver. A 40-year-old with severe obesity loses an estimated 6 to 14 years of life expectancy compared to someone at a healthy weight.

Why traditional approaches have fallen short

The standard advice for weight loss, eat less and move more, is technically accurate and practically insufficient for most people. The body treats sustained caloric restriction as a threat and responds by lowering metabolic rate, increasing hunger hormones (particularly ghrelin), and reducing energy expenditure. This is why the vast majority of people who lose weight through dieting alone regain it within five years.

Behavioral interventions like structured programs, counseling, and group support produce modest results. The Diabetes Prevention Program, one of the best-studied lifestyle interventions, achieved an average of 5.6% body weight loss at one year, with most participants regaining weight over the following decade.

Older weight-loss medications were barely more effective. Orlistat produces roughly 3% more weight loss than placebo. Phentermine-topiramate (Qsymia) managed about 10% but came with significant side effects and cardiovascular concerns. Bariatric surgery works well, producing 25 to 35% weight loss that often lasts, but fewer than 1% of eligible patients undergo the procedure.

What GLP-1 receptor agonists change

GLP-1 receptor agonists are the first class of medications that produce weight loss approaching what surgery delivers, without the surgical risks.

Semaglutide (Wegovy) produces an average of 15% body weight loss over 68 weeks. Tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, pushes that to 22.5%. Retatrutide, a triple agonist currently in phase 3 trials, showed 24.2% weight loss in phase 2 data. For a 250-pound person, that translates to losing 37, 56, or 60 pounds respectively.

These are population averages. Roughly a third of participants in major trials lost 20% or more of their body weight. Some lost over 30%.

Why GLP-1s work differently: Unlike older drugs that targeted a single pathway, GLP-1 receptor agonists work on multiple systems simultaneously. They reduce appetite through hypothalamic signaling, slow gastric emptying so meals feel more filling, improve insulin sensitivity, and dampen food reward pathways in the brain. The body's usual compensatory mechanisms are less able to override these combined effects.

Beyond weight loss

The SELECT trial, which enrolled over 17,000 people, showed that semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 20%, independent of diabetes status. The FLOW trial found a 24% reduction in kidney disease progression.

Active clinical trials are testing GLP-1 agonists for fatty liver disease (MASH), obstructive sleep apnea, osteoarthritis, and polycystic ovary syndrome. Retrospective studies have also found lower rates of Alzheimer's disease in patients taking GLP-1 medications, though randomized trials are still needed to confirm this.

The US spends hundreds of billions per year on obesity-related healthcare. Medications that reduce weight, cardiovascular events, and kidney disease progression at the same time could change that math considerably.

The access problem

These medications work, but they remain out of reach for many of the people who need them most. Brand-name GLP-1s are prohibitively expensive without insurance, and coverage remains inconsistent. Medicare was, until recently, prohibited from covering anti-obesity medications. Many private plans still exclude weight-loss drugs entirely.

Supply shortages compounded the problem through 2023 and 2024, leaving patients cycling on and off medications. Compounding pharmacies stepped in to fill the gap with generic formulations, though the FDA has taken steps to restrict some of these alternatives.

The communities with the highest obesity rates, lower-income and rural populations, face the steepest barriers to access. Telehealth peptide clinics have lowered some barriers, but cost remains the central obstacle.

What happens next

There are over a dozen GLP-1 compounds in late-stage development. Oral formulations are approaching injectable-level efficacy, which would open the door for millions of people who avoid needles. Next-generation compounds like retatrutide and amycretin are producing weight loss numbers that used to require surgery.

Competition is also driving prices down. As more manufacturers enter the market and patents expire, the economics should shift. Medicare coverage for anti-obesity medications, which gained momentum in 2025, would do more to expand access than anything else on the table.

The US obesity crisis took decades to build. No single medication will reverse it. But GLP-1 receptor agonists are, by a wide margin, the most effective weight-loss drugs that have ever existed. For the 100 million American adults living with obesity, the question is no longer whether effective treatment exists. It's whether they can get access to it.

Sources

  1. Hales CM, et al. Prevalence of obesity and severe obesity among adults: United States, 2017-2020. NCHS Data Brief No. 392. CDC. 2022.
  2. Ward ZJ, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2451.
  3. Finkelstein EA, et al. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff. 2009;28(5):w822-w831.
  4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
  5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
  6. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
  7. OECD. Obesity update 2023.
  8. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). N Engl J Med. 2002;346(6):393-403.